Study finds efanesoctocog alfa prophylaxis effective in preventing bleeding in children with severe hemophilia A.
- Once-weekly prophylaxis with efanesoctocog alfa is effective in preventing bleeding in children with severe hemophilia A
- No factor VIII inhibitors developed and most adverse events were nonserious in the study
- Most patients experienced no treated bleeding episodes, spontaneous bleeding episodes, or bleeding into joints
- Mean factor VIII activity was sustained at >40 IU/dL and >10 IU/dL for three and almost seven days after dose administration
- The study concludes that efanesoctocog alfa provided highly efficacious protection against bleeding in children with severe hemophilia A, without burdening treatment regimens.
Source link
Pediatrics, Hematology, Pharmacists